Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL605886 | 1.00 | HRH4 (1.00) | HRH4HRH3 | |
| SCHEMBL606149 | 1.00 | HRH4 (1.00) | HRH4HRH3 | |
| SCHEMBL603049 | 0.94 | HRH4 (0.89) | HRH4HRH3 | |
| SCHEMBL605533 | 0.94 | HRH4 (0.89) | HRH4HRH3 | |
| SCHEMBL606848 | 0.92 | HRH4 (0.85) | HRH4HRH3 | |
| SCHEMBL605168 | 0.92 | HRH4 (0.85) | HRH4HRH3 | |
| SCHEMBL603912 | 0.89 | HRH4 (1.00) | HRH4HRH3 | |
| SCHEMBL2166543 | 0.89 | HRH4 (1.00) | HRH4HRH3 | |
| SCHEMBL2166541 | 0.89 | HRH4 (1.00) | HRH4HRH3 | |
| SCHEMBL604260 | 0.89 | HRH4 (0.80) | HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2040549-B1 | BENZOFURO-AND BENZOTHIENOPYRYIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-23 | — | — | EP | claimed |
| US-7576092-B2 | Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-18 | — | — | US | claimed |
| EP-2040549-A2 | BENZOFURO-AND BENZOTHIENOPYRYIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-01 | — | — | EP | claimed |
| EP-1991550-A1 | AMINO PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Cellzome Limited (GB) | 2008-11-19 | — | — | EP | claimed |
| US-20080015200-A1 | Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | claimed |
| WO-2008008359-A2 | BENZOFURO-AND BENZOTHIENOPYRYIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | WO | claimed |
| EP-1829879-A1 | Amino pyrimidine compounds for the treatment of inflammatory disorders | Cellzome (UK) Ltd. (GB) | 2007-09-05 | — | — | EP | claimed |
| WO-2007090852-A1 | AMINO PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME LIMITED (GB) | 2007-08-16 | — | — | WO | claimed |
| US-10195195-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-02-05 | — | — | US | disclosed |
| EP-3378476-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | Sensorion (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-9688989-B2 | H4 receptor inhibitors for treating tinnitus | SENSORION (FR) | 2017-06-27 | — | — | US | disclosed |
| US-20170056397-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-03-02 | — | — | US | disclosed |
| EP-3130376-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-02-15 | — | — | EP | disclosed |
| US-9526725-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-12-27 | — | — | US | disclosed |
| EP-1829879-A1 | Amino pyrimidine compounds for the treatment of inflammatory disorders | Cellzome (UK) Ltd. (GB) | 2007-09-05 | — | — | EP | disclosed |
| EP-1829879-A1 | Amino pyrimidine compounds for the treatment of inflammatory disorders | Cellzome (UK) Ltd. (GB) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007090853-A1 | ENANTIOMERS OF AMINO PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME (UK) LTD. (GB) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007090853-A1 | ENANTIOMERS OF AMINO PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME (UK) LTD. (GB) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007090852-A1 | AMINO PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME LIMITED (GB) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007090852-A1 | AMINO PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME LIMITED (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015200-A1 | Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor | HRH4, HRH1, HRH2 | HRH4 1/4885HRH3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.